GLPwatch
Papers (12034)
Page 73 of 201, ranked by citation count.
- GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair.
- Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.
- Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
- Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
- Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections.
- DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
- Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?
- Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.
- Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
- Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
- Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism.
- Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.
- Clinical Trial Highlights - GLP-1 agonists.
- Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish.
- Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
- A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.
- Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.
- Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
- Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice.
- Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: Secondary analyses of a randomised controlled trial.
- Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway.
- Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
- Acute interstitial nephritis after treatment with liraglutide.
- Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.
- Semaglutide-associated bullous pemphigoid.
- Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats.
- Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
- Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
- Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
- Neural-Derived Extracellular Vesicles in Clinical Trials: Message in a Bottle.
- Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries.
- Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
- Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.
- Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
- Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice.
- A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
- Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.
- The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.
- Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
- Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.
- Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
- Liraglutide increases islet Ca<sup>2+</sup> oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels.
- A Case Report of a Pregnant Woman With Type 2 Diabetes Mellitus Using Dulaglutide During the First Trimester of Pregnancy.
- Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
- NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.
- Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
- Mode of administration of dulaglutide: implications for treatment adherence.
- Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats.
- Acute Pancreatitis in a Patient Taking Semaglutide.
- Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
- Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
- Exendin-4 protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-3 signaling.
- Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
- Cost effectiveness of liraglutide in type II diabetes: a systematic review.
- The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
- Exendin-4 exhibits cardioprotective effects against high glucose-induced mitochondrial abnormalities: Potential role of GLP-1 receptor and mTOR signaling.
- Semaglutide early intervention attenuated testicular dysfunction by targeting the GLP-1-PPAR-α-Kisspeptin-Steroidogenesis signaling pathway in a testicular ischemia-reperfusion rat model.